{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:13:14Z","timestamp":1725289994074},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5043-9","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T09:22:29Z","timestamp":1543828949000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Harnessing soft tissue sarcoma with low-dose pazopanib \u2013 a matter of blood levels"],"prefix":"10.1186","volume":"18","author":[{"given":"Stefanie L.","family":"Groenland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"5043_CR1","unstructured":"Summary of Product Characteristics of pazopanib. Available from: http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/001141\/WC500094272.pdf"},{"key":"5043_CR2","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220\u20137.","journal-title":"Clin Cancer Res"},{"key":"5043_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2014.144","volume":"111","author":"A Suttle","year":"2014","unstructured":"Suttle A, Ball H, Molimard M, Hutson T, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1\u20138.","journal-title":"Br J Cancer"},{"key":"5043_CR4","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","volume":"22","author":"RB Verheijen","year":"2016","unstructured":"Verheijen RB, Bins S, Mathijssen RHJ, Lolkema MP, van Doorn L, Schellens JHM, et al. Individualized Pazopanib dosing: a prospective feasibility study in Cancer patients. Clin Cancer Res. 2016;22:5738\u201346.","journal-title":"Clin Cancer Res"},{"key":"5043_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","volume":"31","author":"Y Wang","year":"2009","unstructured":"Wang Y, Chia Y, Nedelman J, Schran H, Mahon F. Molimard M. a therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31:579\u201384.","journal-title":"Ther Drug Monit"},{"key":"5043_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Graaf","year":"2012","unstructured":"Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.","journal-title":"Lancet"},{"key":"5043_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","volume":"80","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol. 2017;80:1171\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5043_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","volume":"102","author":"C-F Xu","year":"2010","unstructured":"Xu C-F, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102:1371\u20137.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5043-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:10:40Z","timestamp":1575331840000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5043-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5043"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5043-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication for publication of their clinical details and\/or clinical images was obtained from the patient\/relative of the patient. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1200"}}